ENABLE Lab’s Dr. Rebecca Ashare shares her perspective on the rescheduling of cannabis by the Drug Enforcement Administration to a Schedule III substance and how it will impact the feasibility of generating high-quality rigorous research. For the full article, click here.
Categories